Daynna Wolff to Genetic Testing
This is a "connection" page, showing publications Daynna Wolff has written about Genetic Testing.
Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007 Apr; 9(2):134-43.
Developing a sustainable process to provide quality control materials for genetic testing. Genet Med. 2005 Oct; 7(8):534-49.
Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med. 2005 Jul-Aug; 7(6):444-53.
Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes Cancer. 2020 07; 59(7):422-427.
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 01; 19(1):4-23.
American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities. Genet Med. 2011 Jul; 13(7):676-9.